Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection
about
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Direct-acting antivirals for chronic hepatitis C.Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.Beclabuvir for the treatment of hepatitis C.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).Allosteric mechanism of cyclopropylindolobenzazepine inhibitors for HCV NS5B RdRp via dynamic correlation network analysis.A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China.Direct-acting antivirals for chronic hepatitis C
P2860
Q31051529-9D6CD574-22BB-4855-A992-65681C80061EQ33798031-DEF1CF2B-BB13-4C78-8850-ECD5A1D20606Q34557595-34759E24-AE58-4208-B5AD-659F17889D61Q34580349-1FFF7EFB-AB0B-4B18-AB3C-1AF90AC67B64Q34597529-4251BA27-796B-4140-9C95-22048E4B0C22Q38533619-64E37ECE-E15D-453E-B1C6-E55098854E34Q38544196-BDABBA82-02BB-4D1F-95A4-D950041495D2Q38779980-A7CAD9AB-E244-4A2B-899A-739AC31C2FADQ38893104-A41CC997-7147-4801-B185-816A6408D4D8Q39735463-242C251D-DD67-4E6C-8830-AC0DDF1274DAQ40413372-045797C8-1587-4CC7-B6EA-3C95827F5809Q40536980-54D33EAA-2C0D-470F-8F9C-FD5C3405E433Q41605573-AFB10EBF-622C-4C03-8D46-65A8BD401C7AQ45324124-D281B9E6-6AFD-4559-9AEC-E30FC4506972Q57389418-8E3606A7-6C9F-4541-ABD8-BEDAAFAB9D23
P2860
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Randomized, placebo-controlled ...... r, in HCV genotype 1 infection
@ast
Randomized, placebo-controlled ...... r, in HCV genotype 1 infection
@en
type
label
Randomized, placebo-controlled ...... r, in HCV genotype 1 infection
@ast
Randomized, placebo-controlled ...... r, in HCV genotype 1 infection
@en
prefLabel
Randomized, placebo-controlled ...... r, in HCV genotype 1 infection
@ast
Randomized, placebo-controlled ...... r, in HCV genotype 1 infection
@en
P2093
P2860
P356
P1476
Randomized, placebo-controlled ...... r, in HCV genotype 1 infection
@en
P2093
Anna Berglind
Apinya B Vutikullird
Claudio Pasquinelli
Dennis M Grasela
Diane Sherman
Eric Lawitz
Julie Lemm
Karen D Sims
Menping Liu
P2860
P304
P356
10.1128/AAC.02579-13
P407
P50
P577
2014-04-14T00:00:00Z